Kristina Holubova

Ms. Kristina Holubova

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
JKJan Korabecny
Jan Korabecny
KHKristina Holubova
Kristina Holubova
Eugenie  NepovimovaEugenie Nepovimova
Eugenie Nepovimova
JKJan Krusek
Jan Krusek
MKMartina Kaniakova
Martina Kaniakova
Ondrej SoukupOndrej Soukup
Ondrej Soukup

23 March 2016 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
KHKristina Holubova
Kristina Holubova
LKLenka Kleteckova
Lenka Kleteckova
MSMartina Skurlova
Martina Skurlova
JRJan Ricny
Jan Ricny
ASAles Stuchlik
Ales Stuchlik
KVKarel Vales
Karel Vales

1 September 2018 in Neuropharmacology
Verified
Journal Article
Closed access
MKMartina Kaniakova
Martina Kaniakova
LKLenka Kleteckova
Lenka Kleteckova
KLKatarina Lichnerova
Katarina Lichnerova
KHKristina Holubova
Kristina Holubova
KSKristyna Skrenkova
Kristyna Skrenkova
JKJan Korabecny
Jan Korabecny

1 July 2011 in Neuropharmacology
Verified
Journal Article
Closed access
LRLukas Rambousek
Lukas Rambousek
VBVera Bubenikova-Valesova
Vera Bubenikova-Valesova
PKPetr Kacer
Petr Kacer
KSKamila Syslova
Kamila Syslova
JKJana Kenney
Jana Kenney
KVKarel Vales
Karel Vales

1 January 2017 in Steroids
Verified
Journal Article
Closed access
SASantosh Kumar Adla
Santosh Kumar Adla
BSBarbora Slavikova
Barbora Slavikova
MSMarketa Smidkova
Marketa Smidkova
ETEva Tloustova
Eva Tloustova
MSMartin Svoboda
Martin Svoboda
EKEva Kudova
Eva Kudova

16 April 2014 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
KHKristina Holubova
Kristina Holubova
TNTereza Nekovarova
Tereza Nekovarova
JPJana Pistovcakova
Jana Pistovcakova
ASAlexandra Sulcova
Alexandra Sulcova
ASAles Stuchlã­k
Ales Stuchlã­k
KVKarel Vales
Karel Vales
A number of studies demonstrated a rapid onset of an antidepressant effect of non-competitive NMDA receptor antagonists. Nonetheless, its therapeutic potential is rather limited, due to a high coincidence of negative side-effects. Therefore, the challenge seems to be in the development of NMDA receptor (NMDAR) antagonists displaying antidepressant properties, and at the same time maintaining regular physiological function of the NMDAR. Previous results demonstrated that naturally occurring neurosteroid 3α5β-pregnanolone sulfate shows pronounced inhibitory action by a use-dependent mechanism on the tonically active NMDAR. The aim of the present experiments is to find out whether the treatment with pregnanolone 3αC derivatives affects behavioral response to chronic and acute stress in an animal model of depression. Adult male mice were used throughout the study. Repeated social defeat and forced swimming tests were used as animal models of depression. The effect of the drugs on the locomotor/exploratory activity in the open-field test was also tested together with an effect on anxiety in the elevated plus maze. Results showed that pregnanolone glutamate (PG) did not induce hyperlocomotion, whereas both dizocilpine and ketamine significantly increased spontaneous locomotor activity in the open field. In the elevated plus maze PG displayed anxiolytic-like properties. In forced swimming PG prolonged time to the first floating. Acute treatment of PG disinhibited suppressed locomotor activity in the repeatedly defeated group-housed mice. Aggressive behavior of isolated mice was reduced after the chronic 30-day administration of PG. PG showed antidepressant-like and anxiolytic-like properties in the used tests, with minimal side-effects. Since PG combines GABAA receptor potentiation and use-dependent NMDAR inhibition, synthetic derivatives of neuroactive steroids present a promising strategy for the treatment of mood disorders.